Literature DB >> 18481986

Substances that can change alternative splice-site selection.

Chiranthani Sumanasekera1, David S Watt, Stefan Stamm.   

Abstract

Alternative pre-mRNA splicing is an important element in eukaryotic gene expression, as most of the protein-coding genes use this process to generate multiple protein isoforms from a single gene. An increasing number of human diseases are now recognized to be caused by the selection of 'wrong' alternative exons. Research during the last few years identified a number of low-molecular-mass chemical substances that can change alternative exon usage. Most of these substances act by either blocking histone deacetylases or by interfering with the phosphorylation of splicing factors. How the remaining large number of these substances affect splicing is not yet fully understood. The emergence of these low-molecular-mass substances provides not only probes for studying alternative pre-mRNA splicing, but also opens the door to the possible harnessing of these compounds as drugs to control diseases caused by the selection of 'wrong' splice sites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18481986     DOI: 10.1042/BST0360483

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  34 in total

1.  Splicing of mouse p53 pre-mRNA does not always follow the "first come, first served" principle and may be influenced by cisplatin treatment and serum starvation.

Authors:  Min Yang; Jack Wu; Si-Hung Wu; An-Ding Bi; D Joshua Liao
Journal:  Mol Biol Rep       Date:  2012-06-28       Impact factor: 2.316

Review 2.  Missed threads. The impact of pre-mRNA splicing defects on clinical practice.

Authors:  Diana Baralle; Anneke Lucassen; Emanuele Buratti
Journal:  EMBO Rep       Date:  2009-08       Impact factor: 8.807

3.  Novel nuclear hENT2 isoforms regulate cell cycle progression via controlling nucleoside transport and nuclear reservoir.

Authors:  Natalia Grañé-Boladeras; Christopher M Spring; W J Brad Hanna; Marçal Pastor-Anglada; Imogen R Coe
Journal:  Cell Mol Life Sci       Date:  2016-06-06       Impact factor: 9.261

4.  RNA splicing meets genetic testing: detection and interpretation of splicing defects in genetic diseases.

Authors:  Mario Tosi; Stefan Stamm; Diana Baralle
Journal:  Eur J Hum Genet       Date:  2010-02-24       Impact factor: 4.246

5.  Rapid-response splicing reporter screens identify differential regulators of constitutive and alternative splicing.

Authors:  Ihab Younis; Michael Berg; Daisuke Kaida; Kimberly Dittmar; Congli Wang; Gideon Dreyfuss
Journal:  Mol Cell Biol       Date:  2010-02-01       Impact factor: 4.272

6.  The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region.

Authors:  Eric G Folco; Kaitlyn E Coil; Robin Reed
Journal:  Genes Dev       Date:  2011-03-01       Impact factor: 11.361

Review 7.  Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Antioxid Redox Signal       Date:  2014-12-04       Impact factor: 8.401

8.  Pharmacologic correction of dominant-negative GH1 deficiency causing mutations.

Authors:  Justin S Poling; John A Phillips; Joy D Cogan; Rizwan Hamid
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

9.  High-throughput binding analysis determines the binding specificity of ASF/SF2 on alternatively spliced human pre-mRNAs.

Authors:  Brian Chang; J Levin; William A Thompson; William G Fairbrother
Journal:  Comb Chem High Throughput Screen       Date:  2010-03       Impact factor: 1.339

Review 10.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.